<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The COVID-19 Pandemic Dynamics and Incomes</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Igor</forename><surname>Nesteruk</surname></persName>
							<email>inesteruk@yahoo.com</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hydromechanics</orgName>
								<orgName type="institution">National Academy of Sciences of Ukraine</orgName>
								<address>
									<settlement>Kyiv</settlement>
									<country key="UA">Ukraine</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Infectious Disease Epidemiology Research) Centre</orgName>
								<orgName type="laboratory">SBIDER (Systems Biology</orgName>
								<orgName type="institution">University of Warwick</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oleksii</forename><surname>Rodionov</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Private consulting office</orgName>
								<address>
									<settlement>Kyiv</settlement>
									<country key="UA">Ukraine</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<address>
									<postCode>2024</postCode>
									<settlement>Cambridge</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The COVID-19 Pandemic Dynamics and Incomes</title>
					</analytic>
					<monogr>
						<idno type="ISSN">1613-0073</idno>
					</monogr>
					<idno type="MD5">C26E2B3C64E6AB8B417C6BF30694B09C</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2025-04-23T19:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>COVID-19 pandemic</term>
					<term>epidemic dynamics in Africa</term>
					<term>epidemic dynamics in Europe</term>
					<term>gross domestic product per capita</term>
					<term>non-linear correlation</term>
					<term>statistical methods.1</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Objectives. Large differences in the number of registered SARS-CoV-2 cases per capita in different countries encourage research into the causes of this phenomenon. In particular, the accumulated numbers of cases per million (CC) demonstrated strong linear correlations with the gross domestic product per capita (GDP) and the median age of populations. In this paper the possible correlations between GDP and numbers of cases CC and deaths (DC) per million, case fatality risks CFR=DC/CC, vaccinations and testing levels will be investigated. As well non-linear correlations of CC, DC and CFR values versus vaccinations and testing levels will be considered. Methods. A non-linear correlation and John Hopkins University (JHU) datasets for African and European countries corresponding to August 1, 2022 were used.</p><p>Results. The numbers of CC, DC and CFR increase for richer countries, the same trends were revealed for DC and CFR values in Africa, but opposite ones in Europe. As expected, the testing and vaccination levels increase with the growth of GDP. Higher levels of testing probably allowed revealing more cases and COVID-19 related deaths in rich countries. CC values showed a very strong increasing trend with the increase of numbers of tests per capita (TC). Unexpectedly, the same increasing trend was revealed for CC and DC values versus percentage of fully vaccinated people (VC). Nevertheless, the decrease of CFR with the increase of VC demonstrates a positive effect of vaccinations. Conclusions. In some countries, the number of undetected COVID-19 cases may be tens or even hundreds of times higher than the number of registered ones due to the differences in testing levels and age structure. This fact increases the probability of the appearance of new dangerous SARS-CoV-2 strains and has to be taken into account in further investigations of impact of different factors on the pandemic dynamics.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The general characteristics of the COVID-19 pandemic dynamics require further research despite the vast number of available publications, including studies comparing the COVID-19 pandemic dynamics in different regions and the impact of various factors <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>. In particular, a strong linear correlation was revealed in <ref type="bibr" target="#b17">[18]</ref> between the gross domestic product per capita (GDP) <ref type="bibr">[19]</ref> and the numbers of cases per million (CC) registered in African countries as of February 1, 2022, <ref type="bibr" target="#b18">[20]</ref>. In this study, a non-linear correlation between incomes and values of CC, accumulated numbers of deaths per million (DC) and the case fatality risk (CFR=DC/CC) will be investigated with the use of datasets for African and European countries corresponding to August 1, 2022, <ref type="bibr" target="#b18">[20]</ref>. We will also discuss the possible influence of the accumulated numbers of tests per capita (TC) and the percentage of fully vaccinated people (VC) on the CC, DC and CFR values.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data, the non-linear regression and Fisher test</head><p>We will use the data sets regarding the gross domestic product per capita (GDP) based on purchasing power parity (PPP) available in <ref type="bibr">[19]</ref> and some COVID-19 characteristics reported by John Hopkins University (JHU) as of August 1, 2022, <ref type="bibr" target="#b18">[20]</ref>. The figures corresponding to the versions of files available on September 4, 2022 are presented in supplementary Tables <ref type="table" target="#tab_2">S1 and S2</ref> and shown in the Figure for African (black markers) and European countries (blue markers).</p><p>The following non-linear correlation will be applied:</p><p>; , b&gt;0, x&gt;-c <ref type="bibr" target="#b0">(1)</ref> to find links between GDP, TC, and VC (variable x) and CC, DC, DC/CC, TC, and VC (variable y).</p><p>At γ =1 relationship <ref type="bibr" target="#b0">(1)</ref> reduces to the linear one. It can be also reduced to the linear correlation by using new random variables z and w≡log(x+c), <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b13">14]</ref>:</p><formula xml:id="formula_0">z≡log(y-a)=log(b)+γlog(x+c)<label>(2)</label></formula><p>The constant parameters γ, log(b) and corresponding best fitting lines can be found with the use of standard linear regression formulas <ref type="bibr" target="#b19">[21]</ref> for different values of constant parameters a and c. Their optimal values correspond to the maximum of the correlation coefficient magnitude |r| or the ratio of the Fisher functions F/Fc(k1,k2), (k1=1, k2=n-2, n is the number of observations, i.e., the number of countries in datasets), <ref type="bibr" target="#b5">[ 6,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b13">14]</ref>. The corresponding experimental values F can be calculated with the use of formula (S1), <ref type="bibr" target="#b19">[21]</ref>, the critical values Fc(k1,k2) of the Fisher function at a desired significance or confidence level can be found in <ref type="bibr">[22]</ref>. If F/Fc(k1,k2)&lt;1, the hypothesis about the relationship (1) is not supported by the results of observations. The highest values of F/Fc(k1,k2) correspond to the most reliable hypotheses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The optimal values of parameters for different non-linear correlations (1) are listed in Table <ref type="table" target="#tab_0">1</ref>. Corresponding best fitting lines are shown in the Figure by the black color for African datasets, blue -for Europe and red -for complete datasets (Africa + Europe). Rows 1-3 of Table <ref type="table" target="#tab_0">1</ref> and solid lines in Figure illustrate that the accumulated numbers of cases per million CC always increase with the increase of the incomes. Nevertheless, the number of deaths DC and case fatality risk CFR decrease in richer European countries (see rows 5, 8 and blue dashed and dotted lines; the correlation DC versus GDP is supported at confidence level 0.025; Fc (1, 40) =5.47). What is surprising is the increase in DC and CFR values with increasing income in Africa and for the full data sets (see rows 4, 6, 7, 9 and corresponding dashed and dotted lines; the correlation CFR versus GDP for complete dataset is supported at confidence level 0.005; Fc(1,94) =8.33).</p><p>As expected, the vaccination and testing levels (VC and TC) always increase with rising incomes (see rows 10-15 and corresponding lines). Rows 16 and 18 represent the correlation of CC values versus TC and VC, respectively. The strongest link between the number of cases and the testing level (r=0.9496, and the highest F/Fc(k1,k2) ratio, see row 16) and the strong link between TC and GDP values (see row 12) allows us to conclude that high CC values in rich countries are probably connected with the higher testing level. Numbers of cases and deaths per capita for complete dataset (Africa + Europe) increase with the increase of percentage of vaccinated people VC (see rows <ref type="bibr">18 and 20)</ref>. Opposite trend was revealed only for CFR values (row 22). Thus, the positive effect of vaccinations is visible only in decreasing the probability to die for persons tested positive. To eliminate the influence of the testing level the same correlations were investigated for <ref type="bibr" target="#b14">15</ref>  The characteristics accumulated as of August 1, 2022 are: numbers of cases per million (CC, "circles"), numbers of deaths per million (DC, "crosses"), percentage of fully vaccinated people (VC, "dots"), numbers of test per capita (TC, "squares"). The case fatality risk was calculated with the use of formula CFR=DC/CC and shown by "triangles. Lines represent the best fitting relationships <ref type="bibr" target="#b0">(1)</ref> with the optimal values of parameters listed Table <ref type="table" target="#tab_0">1</ref>: the black color corresponds to African countries, the blue one -to European, the red one -to complete datasets (Africa + Europe).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>The large difference between the number of registered and real COVID-19 cases <ref type="bibr">[23]</ref><ref type="bibr">[24]</ref><ref type="bibr" target="#b20">[25]</ref><ref type="bibr" target="#b21">[26]</ref><ref type="bibr" target="#b22">[27]</ref><ref type="bibr" target="#b23">[28]</ref><ref type="bibr" target="#b24">[29]</ref><ref type="bibr" target="#b25">[30]</ref><ref type="bibr" target="#b26">[31]</ref><ref type="bibr" target="#b27">[32]</ref><ref type="bibr" target="#b28">[33]</ref> has to be taken into account to investigate the effects of different factors on the pandemic dynamics. In particular, different healthcare infrastructures, public health policies, and social behaviors could significantly change the pandemic dynamics and the analysis of these factors needs further investigations. Here we will focus on some specific influence of the testing rate. In particular, the TC values could approach some critical level, which allows revealing almost all COVID-19 cases.</p><p>To check this hypothesis, let us consider the countries with TC&gt;3. Their relatively large number -16 (all countries are located in Europe) -allows drawing some statistical conclusions (see row 17). First, there is no correlation between CC and TC values even for significance level 0.1 (Fc (1, 14) =3.14). It means that 3 or more tests per person were enough to reveal the majority of cases before August 1, 2022. Its average value CCa is approximately 460,834 and can be used to calculate the visibility coefficient <ref type="bibr" target="#b2">(3)</ref> as the ratio of real to registered number of cases.</p><p>There are some theoretical and experimental estimations of the visibility coefficient for different periods of COVID-19 pandemic <ref type="bibr" target="#b9">[10,</ref><ref type="bibr">[23]</ref><ref type="bibr">[24]</ref><ref type="bibr" target="#b20">[25]</ref>. For example, a total testing in Slovakia (89.5% of population was tested on October 31-November 7, 2020) revealed a number of previously a СС СС b = undetected cases, equal to about 1.63% of the population <ref type="bibr">[23,</ref><ref type="bibr">24]</ref>. Taking into account that the number of detected cases in Slovakia was approximately 1% of population <ref type="bibr" target="#b18">[20]</ref>, we can estimate β≈2.63 for that period in Slovakia. As of August 1, 2022 the corresponding value CC=473,844 for Slovakia (see Table <ref type="table" target="#tab_2">S2</ref>) is slightly larger than CCa showing the good detection level in this country with TC=9.41.</p><p>A random testing in two kindergartens and two schools in the Ukrainian city of Chmelnytskii <ref type="bibr" target="#b20">[25]</ref> revealed the value 3.9 in December 2020. Theoretical estimations based on the generalized SIR model <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b9">10]</ref> yielded values from 3.7 to 20.4 for Ukraine and 5.4 for Qatar in different periods of the COVID-19 pandemic. As of August 1, 2022 formula (3) yields the β values 3.8 for Ukraine and 3.0 for Qatar (CC=152,375.8, <ref type="bibr" target="#b18">[20]</ref>). Corresponding visibility coefficients are: 4.4 in Japan; 1.7 in US and 14.7 in India.</p><p>The value CCa = 460,834 and formula (3) is probably not applicable for China and other Zero-COVID countries <ref type="bibr">[34]</ref>, where the total control and maximum suppression of the pandemic were applied. For example, mainland China has achieved the testing level TC=6.46 already on April 11, 2022, <ref type="bibr" target="#b18">[20]</ref>. The value CC=636 registered on August 1, 2022 is much lower than the CCa figure. Nevertheless, CC values in Australia, New Zealand and South Korea (where the zero tolerance policy was not as severe as in China) CC values vary from 317,619 to 384,572 (see <ref type="bibr" target="#b18">[20]</ref>). The testing levels in Hong Kong (TC= 6.59 as of May 24, 2022, <ref type="bibr" target="#b18">[20]</ref>) and in mainland China are very close. The huge difference in the registered numbers of cases per million (CC= 181,231 in Hong Kong as of August 1, 2022, <ref type="bibr" target="#b18">[20]</ref>) probably is connected with much higher values of the tests per case ratio in mainland China, <ref type="bibr" target="#b13">[14]</ref>.</p><p>The lack of appropriate testing makes it especially difficult to detect the first cases of a new disease, which for SARS-CoV-2 probably appeared long before December 2019 <ref type="bibr" target="#b21">[26]</ref>. In particular, theoretical estimates give the date of the appearance of the first case at the beginning of August 2019, <ref type="bibr" target="#b5">[6]</ref>.</p><p>The insufficient testing and high values of visibility coefficients can lead to controversial conclusions about the influence of vaccinations. For example, for complete datasets, unexpected upward trends for CC and DC values with the increasing VC were revealed at the very high significance level (see rows 18 and 20). Similar correlations were also found in <ref type="bibr" target="#b10">[11]</ref> for average daily numbers of COVID-19 cases and deaths. In some countries (e.g., Israel, Japan, New Zealand), high vaccination levels did not prevent new severe pandemic waves <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b13">14]</ref> with record numbers of cases and deaths, <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b13">14]</ref>. Statistical studies support the fact that vaccinations diminished CFR, but their ability to reduce infections should be questioned <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14]</ref> and needs further investigation.</p><p>It would also be interesting to investigate the reasons for the increase in CC and DC values with the increase in incomes (see rows 3 and 6 in Table <ref type="table" target="#tab_0">1</ref>). One of them could be a lower mobility and less number of contacts in poor countries <ref type="bibr" target="#b17">[18]</ref>. The age of population is another important factor in the visible COVID-19 pandemic dynamics <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b29">35]</ref>, since the percentage of asymptomatic (and unregistered) patients is much higher in children <ref type="bibr" target="#b22">[27]</ref><ref type="bibr" target="#b23">[28]</ref><ref type="bibr" target="#b24">[29]</ref><ref type="bibr" target="#b25">[30]</ref>. In particular, a one-year increment in the median year of population yields a 12-18 thousand increase in CC values and 52-83 increase in DC values (both figures correspond December 31, 2022), <ref type="bibr" target="#b29">[35]</ref>. Taking into account the 24 year difference in the median age (18 in Africa and 42 in Europe, [36]) we can expect 288-432 thousand higher CC figures and 1.2-2 thousand higher DC figures in Europe. The huge number of undetected COVID-19 cases increases the probability of the appearance of new dangerous SARS-CoV-2 variants.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>Non-linear correlation analysis (using JHU datasets for Europe and Africa corresponding to August 1, 2022) demonstrated that the numbers of COVID-19 cases CC and deaths DC per capita and case fatality risks CFR=DC/CC increase for richer countries. The same trends were revealed for DC and CFR values in Africa, but opposite ones in Europe. As expected, the testing and vaccination levels increase with the growth of GDP. Higher levels of testing probably allowed revealing more cases and COVID-19 related deaths in rich countries. CC values showed a very strong increasing trend with the increase of numbers of tests per capita (TC). Unexpectedly, the same increasing trend was revealed for CC and DC values versus percentage of fully vaccinated people (VC). Nevertheless, the decrease of CFR with the increase of VC demonstrates a positive effect of vaccinations.</p><p>In some countries, the number of undetected COVID-19 cases may be tens or even hundreds of times higher than the number of registered ones due to the differences in testing levels and age structure. This fact increases the probability of the appearance of new dangerous SARS-CoV-2 strains and has to be taken into account in further investigations of impact of different factors on the pandemic dynamics.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary tables</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table S1. Gross domestic product per capita (GDP) based on purchasing power parity (PPP), accumulated and daily characteristics of the COVID-19 pandemic dynamics in</head></div><figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="4,46.80,63.55,430.30,252.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Optimal values of parameters in eq. (1), correlation coefficients and the results of Fisher test applications for Africa, Europe and complete datasets (Africa + Europe).</head><label>1</label><figDesc>European countries with TC&gt;3. Corresponding CC, DC and CFR values demonstrate decreasing Relationships</figDesc><table><row><cell>( y a b x с g ) = + +</cell><cell>a ³</cell><cell>0</cell></row></table><note>versus accumulated tests per capita values (TC), variable x in eq. (1) g Figure 1: Characteristics of the COVID-19 pandemic in Africa (black) and Europe (blue) versus gross domestic product based on purchasing power parity GDP (PPP) per capita in international US dollars</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc>-1; 8 -5; 9 -18; 10 -19; 11 -29; 12 -30; June: 13 -2; 14 -12; 15 -15; 16 -16; 17 -19; 18 -20; 19 -22; 20 -23; July: 21 -3; 22 -17; 23 -24; 24 -27; 25 -31; August: 26 -2; 27 -7; 28 -14; 29 -21.</figDesc><table><row><cell>Faso Guinea-Tunisia</cell><cell>12300</cell><cell>17.53 28 52.02 26</cell><cell>4082.066 92040.93</cell><cell>83.466 2368.191</cell><cell>69.368 19 379.013 14</cell></row><row><cell>Burundi Bissau Uganda</cell><cell>2961</cell><cell>0.13 27 27.12 27</cell><cell>3609.85 3691.081</cell><cell>3.028 79.121</cell><cell>128.377 18 59.955 19</cell></row><row><cell>Cameroon Kenya Zambia</cell><cell>3776</cell><cell>4.51 23 17.65 29 26.49</cell><cell>4419.892 6369.872 16919.88</cell><cell>70.996 107.008 206.182</cell><cell>100.416 18 70.335 19 180.456 15</cell></row><row><cell>Cape Lesotho Zimbabwe</cell><cell>2523</cell><cell>52.4 27 38.25 22 29.35</cell><cell>105732.9 14920.31 16030.36</cell><cell>697.368 307.699 348.704</cell><cell>no data 201.508 18 148.804 19</cell></row><row><cell cols="2">Verde Liberia Figures corresponding to different days in 2022: February: 1 -13; 2 -18;</cell><cell>44.83 21</cell><cell>1451.453</cell><cell>56.61</cell><cell>26.923 5</cell></row><row><cell>March: 3 -7; 4 -10; 5 -12; 6 -24;</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Central Libya May: 7</cell><cell></cell><cell>22.82 23 18.11 26</cell><cell>2705.44 74772.13</cell><cell>20.707 954.823</cell><cell>17.364 18 no data</cell></row><row><cell>African Madagascar</cell><cell></cell><cell>4.64 27</cell><cell>2299.481</cell><cell>48.693</cell><cell>15.623 16</cell></row><row><cell>Republic Malawi</cell><cell></cell><cell>9.72 27</cell><cell>4395.482</cell><cell>134.089</cell><cell>29.628 19</cell></row><row><cell>Chad Mali</cell><cell></cell><cell>21.01 28 6.84 27</cell><cell>432.894 1425.612</cell><cell>11.234 33.737</cell><cell>12.74 19 32.326 19</cell></row><row><cell>Comoros Mauritania</cell><cell></cell><cell>46.5 25 30.56 23</cell><cell>10120.18 13559.99</cell><cell>194.736 214.952</cell><cell>122.062 9 216.286 19</cell></row><row><cell>Congo Mauritius</cell><cell></cell><cell>11.21 25 75.27 27</cell><cell>4245.343 188503.5</cell><cell>66.143 779.882</cell><cell>67.692 7 987.58 18</cell></row><row><cell>Cote Morocco</cell><cell></cell><cell>30.46 27 63.29 24</cell><cell>3106.748 34014.06</cell><cell>29.514 437.958</cell><cell>56.075 19 316.606 14</cell></row><row><cell>D'Ivoire Mozambique</cell><cell></cell><cell>39.92 28</cell><cell>7157.792</cell><cell>69.052</cell><cell>41.83 19</cell></row><row><cell>Democratic Namibia</cell><cell></cell><cell>2.58 27 19.07 25</cell><cell>961.196 66894.43</cell><cell>14.495 1609.39</cell><cell>10.899 19 417.384 19</cell></row><row><cell>Republic Niger</cell><cell></cell><cell>11.83 25</cell><cell>360.516</cell><cell>12.316</cell><cell>10.08 10</cell></row><row><cell>of Congo Nigeria</cell><cell></cell><cell>13.2 28</cell><cell>1222.94</cell><cell>14.747</cell><cell>24.74 19</cell></row><row><cell>Djibouti Rwanda</cell><cell></cell><cell>17.25 24 77.91 27</cell><cell>14191.94 9823.436</cell><cell>170.955 108.9</cell><cell>280.159 11 411.155 20</cell></row><row><cell>Egypt Sao Tome</cell><cell></cell><cell>35.33 24 45.1 25</cell><cell>4719.337 27408.37</cell><cell>226.657 336.162</cell><cell>109.415 7 21.039 17</cell></row><row><cell>and Principe</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Equatorial Senegal</cell><cell></cell><cell>13.09 23 6.35</cell><cell>10242.49 5180.094</cell><cell>111.963 116.61</cell><cell>296.46 16 65.303 8</cell></row><row><cell>Guinea Seychelles</cell><cell></cell><cell>76.12 27</cell><cell>426683.6</cell><cell>1577.909</cell><cell>no data</cell></row><row><cell>Eritrea Sierra Leone</cell><cell></cell><cell>No data 25.77 27</cell><cell>2777.109 918.457</cell><cell>28.451 14.844</cell><cell>6.544 3 50.889 14</cell></row><row><cell>Algeria Eswatini Somalia</cell><cell>13002</cell><cell>15.51 11 28.69 27 11.96 24</cell><cell>6056.096 61464.21 1583.304</cell><cell>155.643 1188.488 79.751</cell><cell>no data 461.016 19 29.37 20</cell></row><row><cell>Angola Ethiopia South Africa</cell><cell>7360</cell><cell>22.14 27 30.52 25 32.35 26</cell><cell>2964.922 4092.664 67435.12</cell><cell>55.414 62.918 1717.093</cell><cell>46.91 13 41.774 19 431.667 19</cell></row><row><cell>Benin Gabon South Sudan</cell><cell>4137</cell><cell>20.66 28 10.98 28 13.69 27</cell><cell>2101.733 20720.76 1649.847</cell><cell>12.541 130.703 12.839</cell><cell>no data 683.374 18 38.172 18</cell></row><row><cell>Botswana Gambia Sudan</cell><cell>19287</cell><cell>58.44 27 13.54 27 9.94 12</cell><cell>125740.7 4575.146 1379.979</cell><cell>1070.15 139.398 108.57</cell><cell>882.839 9 58.974 6 12.33 1</cell></row><row><cell>Burkina Ghana Tanzania</cell><cell>2663</cell><cell>7.64 29 24.4 25 23.24 27</cell><cell>955.989 5120.666 589.888</cell><cell>17.511 44.376 13.226</cell><cell>14.695 4 75.084 18 7.168 2</cell></row><row><cell>Guinea Togo</cell><cell></cell><cell>18.98 28 16.49 28</cell><cell>2764.429 4406.334</cell><cell>32.885 32.274</cell><cell>52.351 19 86.722 19</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table S2 . Gross domestic product per capita (GDP) based on purchasing power parity (PPP), accumulated and daily characteristics of the COVID-19 pandemic dynamics in European countries as of August 1, 2022 (figures corresponding to other days are specified in notes)</head><label>S2</label><figDesc></figDesc><table><row><cell>Estonia</cell><cell>44.778</cell><cell>63.5</cell><cell>441332.6</cell><cell>1971.851</cell><cell>2577.757</cell></row><row><cell>Finland</cell><cell>58.010</cell><cell>78.37 35</cell><cell>211531</cell><cell>905.348</cell><cell>1994.022</cell></row><row><cell>France</cell><cell>56.036</cell><cell>78.63</cell><cell>503224.3</cell><cell>2258.135</cell><cell>4126.754</cell></row><row><cell>Germany</cell><cell>63.271</cell><cell>76.01</cell><cell>371147.5</cell><cell>1728.24</cell><cell>1574.021</cell></row><row><cell>Greece</cell><cell>35.596</cell><cell>73.08</cell><cell>416397.4</cell><cell>2967.728</cell><cell>8088.12 26</cell></row><row><cell>Hungary</cell><cell>40.944</cell><cell>63.86 34</cell><cell>202422.7</cell><cell>4818.85</cell><cell>1127.081</cell></row><row><cell>Iceland</cell><cell>64.621</cell><cell>78.36 10</cell><cell>545876</cell><cell>483.346</cell><cell>3709.574</cell></row><row><cell>Ireland</cell><cell>124.596</cell><cell>81.18</cell><cell>329721.7</cell><cell>1539.148</cell><cell>2476.135</cell></row><row><cell>Italy</cell><cell>50.216</cell><cell>80.95</cell><cell>355493.4</cell><cell>2906.922</cell><cell>3795.998</cell></row><row><cell>Kosovo</cell><cell>13.964</cell><cell>46.25</cell><cell>142944.2</cell><cell>1779.346</cell><cell>1036.053</cell></row><row><cell>Latvia</cell><cell>37.330</cell><cell>69.69 29</cell><cell>461241.4</cell><cell>3146.347</cell><cell>3876.137</cell></row><row><cell>Liechtenstein</cell><cell>No data</cell><cell>67.72 32</cell><cell>479341.2</cell><cell>2202.925</cell><cell>2321.576 3</cell></row><row><cell>Lithuania</cell><cell>46.479</cell><cell>67.37</cell><cell>424716.3</cell><cell>3304.684</cell><cell>3128.553</cell></row><row><cell>Country Luxembourg</cell><cell>GDP (PPP) 140.694</cell><cell>People No data</cell><cell>Total cases 441487.1</cell><cell>Total 1734.653</cell><cell>Total tests 6725.731</cell></row><row><cell>Malta</cell><cell>per capita 54.647</cell><cell>fully 89.28</cell><cell>per million 214294.1</cell><cell>deaths per 1507.362</cell><cell>per thousand 3703.589</cell></row><row><cell>Moldova</cell><cell>Int$, [19] 16.719</cell><cell>vaccinated 34.74 17</cell><cell>CC, [20] 173831.8</cell><cell>million, 3791.598</cell><cell>TC*1000, [20] no data</cell></row><row><cell>Monaco</cell><cell>No data</cell><cell>per hundred, 69.96 1</cell><cell>385133.3</cell><cell>DC, [20] 1662.76</cell><cell>no data</cell></row><row><cell>Montenegro</cell><cell>24.878</cell><cell>%, VC, [20] 45.27</cell><cell>414061.1</cell><cell>4376.779</cell><cell>no data</cell></row><row><cell>Albania Netherlands</cell><cell>17.383 68.572</cell><cell>43.97 33 68.35 32</cell><cell>109424.4 477054.9</cell><cell>1242.858 1290.389</cell><cell>565.336 26 1753.393</cell></row><row><cell>Andorra North</cell><cell>63.600 19.726</cell><cell>67.66 37 39.82 33</cell><cell>575802.8 156028.8</cell><cell>1935.876 4456.267</cell><cell>3799.719 7 986.118 26</cell></row><row><cell>Austria Macedonia</cell><cell>64.751</cell><cell>76.44 5</cell><cell>535081.7</cell><cell>2277.159</cell><cell>21272.13 27</cell></row><row><cell>Belarus Norway</cell><cell>21.686 77.808</cell><cell>66.52 33 74.96</cell><cell>103781.5 269485.9</cell><cell>743.148 670.551</cell><cell>1380.273 12 2064.505</cell></row><row><cell>Belgium Poland</cell><cell>61.587 41.685</cell><cell>78.85 58.81</cell><cell>381107.7 158461</cell><cell>2778.558 3042.989</cell><cell>2955.332 23 964.881 20</cell></row><row><cell>Bosnia and Portugal</cell><cell>17.471 40.805</cell><cell>25.87 4 86.54 32</cell><cell>117815.3 519445</cell><cell>4849.366 2392.882</cell><cell>458.37 2 4161.808</cell></row><row><cell>Herzegovina Romania</cell><cell>36.622</cell><cell>41.98 18</cell><cell>158772.8</cell><cell>3415.205</cell><cell>1099.946 9</cell></row><row><cell>Bulgaria San Marino</cell><cell>28.593 70.139</cell><cell>29.99 70.03 15</cell><cell>175689.8 589403.2</cell><cell>5431.995 3496.711</cell><cell>1463.898 26 no data</cell></row><row><cell>Croatia Serbia</cell><cell>36.201 23.904</cell><cell>55.33 31 47.71 27</cell><cell>292302.4 309830.7</cell><cell>4021.049 2370.063</cell><cell>1212.45 27 1433.869</cell></row><row><cell>Cyprus Slovakia</cell><cell>48.443 38.620</cell><cell>72.03 30 50.73 33</cell><cell>628244 473844</cell><cell>1244.41 3712.996</cell><cell>32925.83 11 9405.66 26</cell></row><row><cell>Czechia Slovenia</cell><cell>47.527 48.534</cell><cell>65.49 57.67 28</cell><cell>379468.8 511303.1</cell><cell>3853.198 3161.257</cell><cell>5193.488 26 2517.858</cell></row><row><cell>Denmark Spain</cell><cell>69.273 46.413</cell><cell>81.69 85.53 35</cell><cell>552355.7 278530.9</cell><cell>1139.516 2331.568</cell><cell>11043.26 26 1961.848</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors are grateful to Robin Thompson, Matt Keeling, and Paul Brown for their support and providing very useful information. Igor Nesteruk was supported by INI-LMS Solidarity Programme at the University of Warwick, UK.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest</head><p>The authors declare no conflict of interests</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical Approval statement</head><p>The study does not use any experiments with humans or animals. The data sources are available on the Internet. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fisher function</head><p>The experimental values of the Fisher function can be calculated with the use of the formula:</p><p>(S1) where n is the number of observations (number of countries and regions taken for statistical analysis); m=2 is the number of parameters in the linear regression equation ( <ref type="formula">2</ref>  </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Eco-epidemiological assessment of the COVID-19 epidemic in China</title>
		<author>
			<persName><forename type="first">P</forename><surname>Byass</surname></persName>
		</author>
		<idno type="DOI">10.1101/2020.03.29.20046565</idno>
	</analytic>
	<monogr>
		<title level="j">medRxiv</title>
		<imprint>
			<date type="published" when="2020-02">January-February 2020. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">CoronaTracker: Worldwide COVID-19 Outbreak Data Analysis and Prediction</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hamzah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Binti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nazri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Ligot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bull. World Health Organ</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Analysis and forecast of COVID-19 spreading in China, Italy and France</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Piazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chaos Solitons Fractals</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page">109761</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Covid-19 Outbreak Progression in Italian Regions: Approaching the Peak by the End of March in Northern Italy and First Week of April in Southern Italy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Distante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Piscitelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Environ. Res. Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">3025</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">COVID-19: Development of a robust mathematical model and simulation package with consideration for ageing population and time delay for control action and resusceptibility</title>
		<author>
			<persName><surname>Ky</surname></persName>
		</author>
		<author>
			<persName><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><surname>Gui</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.physd.2020.132599</idno>
		<ptr target="https://doi.org/10.1016/j.physd.2020.132599" />
	</analytic>
	<monogr>
		<title level="j">Physica D: Nonlinear Phenomena</title>
		<imprint>
			<biblScope unit="volume">411</biblScope>
			<biblScope unit="page">132599</biblScope>
			<date type="published" when="2020-10">October 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">COVID19 pandemic dynamics</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-981-33-6416-5</idno>
		<ptr target="https://link.springer.com/book/10.1007/978-981-33-6416-5" />
		<imprint>
			<date type="published" when="2021">2021</date>
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Associating the Change in New COVID-19 Cases to GDP per Capita in 38 European Countries in the First Wave of the Pandemic</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pardhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Drydakis</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2020.582140</idno>
	</analytic>
	<monogr>
		<title level="j">Front Public Health</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">582140</biblScope>
			<date type="published" when="2021-01-20">2021 Jan 20</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis</title>
		<author>
			<persName><forename type="first">Ryan</forename><forename type="middle">M</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J D</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">M</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Catherine</forename><surname>Pigott</surname></persName>
		</author>
		<author>
			<persName><surname>Bisignano</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(22)00484-6</idno>
		<ptr target="https://doi.org/10.1016/S0140-6736(22)00484-6" />
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">399</biblScope>
			<biblScope unit="page" from="2351" to="2380" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">COVID-19 dynamics after a national immunization program in Israel</title>
		<author>
			<persName><forename type="first">H</forename><surname>Rossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shilo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gorfine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Shalit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Segal</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-021-01337-2</idno>
		<ptr target="https://doi.org/10.1038/s41591-021-01337-2" />
	</analytic>
	<monogr>
		<title level="j">NATURE MEDICINE</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1055" to="1061" />
			<date type="published" when="2021-06">June 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Influence of Possible Natural and Artificial Collective Immunity on New COVID-19 Pandemic Waves in Ukraine and Israel</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<idno type="DOI">10.14218/ERHM.2021.00044</idno>
	</analytic>
	<monogr>
		<title level="j">Explor Res Hypothesis Med</title>
		<imprint>
			<date type="published" when="2021-11-11">2021. Nov 11, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Trends of the COVID-19 dynamics in 2022 and 2023 vs. the population age, testing and vaccination levels</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<idno type="DOI">10.3389/fdata.2023.1355080</idno>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Big Data</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1355080</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Comparative study of linear regression and SIR models of COVID-19 propagation in Ukraine before vaccination</title>
		<author>
			<persName><forename type="first">Alireza</forename><surname>Mohammadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ievgen</forename><surname>Meniailov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kseniia</forename><surname>Bazilevych</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sergey</forename><surname>Yakovlev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dmytro</forename><surname>Chumachenko</surname></persName>
		</author>
		<idno type="DOI">10.32620/reks.2021.3.01</idno>
		<ptr target="https://doi.org/10.32620/reks.2021.3.01" />
	</analytic>
	<monogr>
		<title level="j">Radioelectronic and Computer Systems</title>
		<imprint>
			<biblScope unit="volume">0</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="5" to="18" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Should we ignore SARS-CoV-2 disease?</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0950268824000487</idno>
	</analytic>
	<monogr>
		<title level="j">Epidemiology and Infection</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page">e57</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Impact of vaccination and testing levels on the COVID-19 waves</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<idno type="DOI">10.13140/RG.2.2.12941.35047</idno>
	</analytic>
	<monogr>
		<title level="j">Research Gate</title>
		<imprint>
			<date type="published" when="2024-06-13">Uploaded June 13, 2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The association between the dynamics of COVID-19, related measures, and daytime population in Tokyo</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takeuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kokaze</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-022-06716-4</idno>
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">3063</biblScope>
			<date type="published" when="2022-02">Feb 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effective Utilization of Data for Predicting COVID-19 Dynamics: An Exploration through Machine Learning Models</title>
		<author>
			<persName><forename type="first">D</forename><surname>Chumachenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dudkina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yakovlev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chumachenko</surname></persName>
		</author>
		<idno type="DOI">10.1155/2023/9962100</idno>
		<ptr target="https://doi.org/10.1155/2023/9962100" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Telemedicine and Applications</title>
		<imprint>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2023">2023. 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A proficient approach to forecast COVID-19 spread via optimized dynamic machine learning models</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Alali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Harrou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sun</forename><forename type="middle">Y</forename></persName>
		</author>
		<idno type="DOI">10.1038/s41598-022-06218-3,35165290</idno>
		<ptr target="https://doi.org/10.1038/s41598-022-06218-3,35165290" />
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Coronavirus and incomes: the COVID-19 pandemic dynamics in Africa in February 2022</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nesteruk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rodionov</surname></persName>
		</author>
		<idno type="DOI">10.1101/2022.04.22.22274058</idno>
		<idno>doi:</idno>
		<ptr target="https://doi.org/10.1101/2022.04.22.22274058" />
	</analytic>
	<monogr>
		<title level="j">MedRxiv</title>
		<imprint>
			<date type="published" when="2022-04-26">April 26, 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<ptr target="https://github.com/owid/covid-19-data/tree/master/public/data" />
		<title level="m">COVID-19 Data Repository by the Center for Systems Science and Engineering</title>
				<imprint>
			<publisher>JHU</publisher>
		</imprint>
		<respStmt>
			<orgName>CSSE) at Johns Hopkins University</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Applied regression analysis</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Draper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Smith</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1998">1998</date>
			<publisher>John Wiley</publisher>
		</imprint>
	</monogr>
	<note>3rd ed</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m">An experiment with mass testing for COVID-19 was conducted in Khmelnytsky| Podillya News</title>
				<imprint/>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Estimating the early death toll of COVID-19 in the United States</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Weinberger</surname></persName>
		</author>
		<idno type="DOI">10.1101/2020.04.15.2006643</idno>
		<ptr target="https://doi.org/10.1101/2020.04.15.2006643" />
		<imprint>
			<date type="published" when="2020-04">2020 Apr</date>
			<pubPlace>MEDRXIV</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">Preprint</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Impact of Age and Sex on COVID-19 Severity Assessed From Radiologic and Clinical Findings</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Statsenko</surname></persName>
		</author>
		<idno type="DOI">10.3389/fcimb.2021.777070</idno>
		<ptr target="https://doi.org/10.3389/fcimb.2021.777070" />
	</analytic>
	<monogr>
		<title level="j">Front. Cell. Infect. Microbiol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">2021</biblScope>
			<date type="published" when="2022-02-25">25 February 2022</date>
		</imprint>
	</monogr>
	<note>Sec. Clinical Microbiology</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Agedependent effects in the transmission and control of COVID-19 epidemics</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klepac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Prem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jit</surname></persName>
		</author>
		<author>
			<persName><surname>Cmmid Covid-19</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Eggo</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-020-0962-9</idno>
		<idno type="PMID">32546824</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1205" to="1211" />
			<date type="published" when="2020-06-16">2020 Aug. 2020 Jun 16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years -PROTECT Cohort</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Fowlkes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lutrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gwynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ellingson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferraris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leclair</surname></persName>
		</author>
		<idno type="DOI">10.15585/mmwr.mm7111e1</idno>
	</analytic>
	<monogr>
		<title level="j">MMWR Morb. Mortal. Wkly. Rep</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="422" to="428" />
			<date type="published" when="2021-07">July 2021-February 2022. 2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.3390/vaccines10071049</idno>
		<idno type="PMID">35891214</idno>
		<idno type="PMCID">PMC9321237</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccines</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">1049</biblScope>
			<date type="published" when="2022-06-30">2022 Jun 30</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Parallel dynamics in the yield of universal SARS-CoV-2 admission screening and population incidence</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Scheier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wolfensberger</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-023-33824-6</idno>
		<ptr target="https://doi.org/10.1038/s41598-023-33824-6" />
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">7296</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Asymptomatic COVID-19 infection: diagnosis, transmission, population characteristics</title>
		<author>
			<persName><forename type="first">Y</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ Supportive &amp; Palliative Care</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="e220" to="e227" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kronbichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kresse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Effenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Shin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijid.2020.06.052</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="180" to="186" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Population age as a key factor in the COVID-19 pandemic dynamics</title>
		<author>
			<persName><forename type="first">Igor</forename><surname>Nesteruk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Matt</forename><surname>Keeling</surname></persName>
		</author>
		<idno type="DOI">10.21203/rs.3.rs-3682693/v1</idno>
		<ptr target="https://doi.org/10.21203/rs.3.rs-3682693/v1" />
		<imprint>
			<date type="published" when="2023-11-30">November 30, 2023</date>
		</imprint>
		<respStmt>
			<orgName>Research Square</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Preprint</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
